1. 1. Chavda VP, Feehan J, Apostolopoulos V. Inflammation: The Cause of All Diseases. Cells. 2024; 13(22):1906. https://doi.org/10.3390/cells13221906 https://doi.org/10.3390/cells13221906 PMid:39594654 PMCid:PMC11592557

   2. Vasileia Ismini Alexaki. Adipose tissue-derived mediators of systemic inflammation and metabolic control. Curr Opin Endocr Metab Res. 2024; 37. https://doi.org/10.1016/j.coemr.2024.100560 https://doi.org/10.1016/j.coemr.2024.100560

   3. Soták M, Clark M, Suur BE, et al. Inflammation and resolution in obesity. Nat Rev Endocrinol. 2025; 21:45-61. https://doi.org/10.1038/s41574-024-01047-y https://doi.org/10.1038/s41574-024-01047-y PMid:39448830

   4. Savulescu-Fiedler I, Mihalcea R, Dragosloveanu S, Scheau C, Baz RO, Caruntu A, Scheau AE, et al. The Interplay between Obesity and Inflammation. Life. 2024; 14:856. https://doi.org/10.3390/life14070856 https://doi.org/10.3390/life14070856 PMid:39063610 PMCid:PMC11277997

   5. Turner L, Wanasinghe A, Brunori P, Santosa S. Is Adipose Tissue Inflammation the Culprit of Obesity-Associated Comorbidities? Obesity Reviews. 2025; 26(11):e13956, https://doi.org/10.1111/obr.13956 https://doi.org/10.1111/obr.13956 PMid:40533358 PMCid:PMC12531753

   6. Palanivel JA, Millington GWM. Obesity-induced immunological effects on the skin. Skin Health Dis. 2023; 3(3):e160. https://doi.org/10.1002/ski2.160 https://doi.org/10.1002/ski2.160 PMid:37275420 PMCid:PMC10233091

   7. Unamuno X, Frühbeck G, Catalán V. Adipose Tissue. In: Encyclopedia of Endocrine Diseases. Elsevier; 2019:370-384. https://doi.org/10.1016/B978-0-12-801238-3.65163-2

   8. Li J, Li Y, Zhou X., et al. Adipocytes orchestrate obesity-related chronic inflammation through β2-microglobulin. Sig Transduct Target Ther. 2025; 10:394. https://doi.org/10.1038/s41392-025-02486-3 https://doi.org/10.1038/s41392-025-02486-3 PMid:41330906 PMCid:PMC12672573

   9. https://my.clevelandclinic.org/health/body/24052-adipose-tissue-body-fat

   10. Zhang M, Hu T, Zhang S, et al. Associations of Different Adipose Tissue Depots with Insulin Resistance: A Systematic Review and Meta-analysis of Observational Studies. Sci Rep. 2015; 5:18495. https://doi.org/10.1038/srep1849 https://doi.org/10.1038/srep18495 PMid:26686961 PMCid:PMC4685195

   11. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, et al. Dynamics of fat cell turnover in humans. Nature. 2008; 453(7196):783-7. https://doi.org/10.1038/nature06902 https://doi.org/10.1038/nature06902 PMid:18454136

   12. Dichi I, Simão AN, Vannucchi H, Curi R, Calder PC. Metabolic syndrome: epidemiology, pathophysiology, and nutrition intervention. J Nutr Metab. 2012; 2012:584541. https://doi.org/10.1155/2012/584541 PMid:22778922 PMCid:PMC3384958

   13. Bensussen A, Torres-Magallanes JA and Roces de Álvarez-Buylla E Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front. Immunol. 2023; 14:1014778. https://doi.org/10.3389/fimmu.2023.1014778 https://doi.org/10.3389/fimmu.2023.1014778 PMid:37026009 PMCid:PMC10070947

   14. Zhang Y, Gao W, Li B, et al. The association between the visceral obesity indices and the future diabetes mellitus risk: A prospective cohort study. Diabetes Obes Metab. 2025; 27(8): 4490-4498. https://doi.org/10.1111/dom.16492 https://doi.org/10.1111/dom.16492 PMid:40432378

   15. Lin M, Zhou Y, Wu R, Li S, Ni X, Xiao J, et al. Temporal Relationship Between Visceral Fat and Inflammation, and Their Joint Effect on Cardiometabolic Diseases: Evidence from the China Health and Retirement Longitudinal Study (CHARLS). J Inflamm Res. 2025; 18:14913-14926. https://doi.org/10.2147/JIR.S539644 https://doi.org/10.2147/JIR.S539644 PMid:41181368 PMCid:PMC12577634

   16. Bettinetti-Luque M, Trujillo-Estrada L, Garcia-Fuentes E, Andreo-Lopez J, Sanchez-Varo R, Garrido-Sánchez L, et al. Adipose tissue as a therapeutic target for vascular damage in Alzheimer’s disease. British Journal of Pharmacology. 2024; 181(6):840-878. https://doi.org/10.1111/bph.16243 https://doi.org/10.1111/bph.16243 PMid:37706346

   17. 17. Gemma Alderton. Obesity and inflammation. Science.2020;370(6515):419.1-419 https://doi.org/10.1126/science.370.6515.419-a https://doi.org/10.1126/science.370.6515.419-a

   18. Ming Ma, Wei Jiang, Rongbin Zhou. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity. 2024; 57(4). https://doi.org/10.1016/j.immuni.2024.03.002 https://doi.org/10.1016/j.immuni.2024.03.002 PMid:38599169

   19. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol. 2010; 11:373-384. https://doi.org/10.1038/ni.1863 https://doi.org/10.1038/ni.1863 PMid:20404851

   20. Kaur S, Auger C, Jeschke MG. Adipose tissue metabolic function and dysfunction: impact of burn injury. Front Cell Dev Biol. 2020; 8:599576. https://doi.org/10.3389/fcell.2020.599576 https://doi.org/10.3389/fcell.2020.599576 PMid:33251224 PMCid:PMC7676399

   21. Sikora JP, Karawani J, Sobczak J. Neutrophils and the Systemic Inflammatory Response Syndrome (SIRS). International Journal of Molecular Sciences. 2023; 24(17):13469. https://doi.org/10.3390/ijms241713469 https://doi.org/10.3390/ijms241713469 PMid:37686271 PMCid:PMC10488036

   22. Baddam S, Burns B. Systemic Inflammatory Response Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2025. https://www.ncbi.nlm.nih.gov/books/NBK547669/

   23. Shrestha M, Kumar M. Systemic inflammatory response syndrome: the current status. November Journal of Universal College of Medical Sciences. 2018; 6(1):56 https://doi.org/10.3126/jucms.v6i1.21732 https://doi.org/10.3126/jucms.v6i1.21732

   24. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets – an updated view. Mediators Inflamm. 2013; 2013:165974. https://doi.org/10.1155/2013/165974 https://doi.org/10.1155/2013/165974 PMid:23853427 PMCid:PMC3703895

   https://my.clevelandclinic.org/health/diseases/multiple-organ-dysfunction-syndrome

   26. 26. Wrba L, Halbgebauer R, Roos J, et al. Adipose tissue: a neglected organ in the response to severe trauma?. Cell Mol Life Sci. 2022; 79(207). https://doi.org/10.1007/s00018-022-04234-0 https://doi.org/10.1007/s00018-022-04234-0 PMid:35338424 PMCid:PMC8956559

   27. Pachler C, Ikeoka D, Plank J, Weinhandl H, Suppan M, Mader JK, et al. Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans. Am J Physiol Endocrinol Metab. 2007; 293(3):E690-6. https://doi.org/10.1152/ajpendo.00034.2007 https://doi.org/10.1152/ajpendo.00034.2007 PMid:17578890

   28. Prasai A, El Ayadi A, Mifflin RC, Wetzel MD, Andersen CR, Redl H, et al. Characterization of Adipose-Derived Stem Cells Following Burn Injury. Stem Cell Rev Rep. 2017; 13(6):781-792. https://doi.org/10.1007/s12015-017-9721-9 https://doi.org/10.1007/s12015-017-9721-9 PMid:28646271 PMCid:PMC5730636

   29. Saraf MK, Herndon DN, Porter C, Toliver-Kinsky T, Radhakrishnan R, Chao T, et al. Morphological Changes in Subcutaneous White Adipose Tissue After Severe Burn Injury. J Burn Care Res. 2016; 37(2):e96-103. https://doi.org/10.1097/BCR.0000000000000292 https://doi.org/10.1097/BCR.0000000000000292 PMid:26284641 PMCid:PMC4749448

   30. Charles-Messance H, Mitchelson KAJ, De Marco Castro E, Sheedy FJ, Roche HM. Regulating metabolic inflammation by nutritional modulation. J Allergy Clin Immunol. 2020; 146(4):706-720. https://doi.org/10.1016/j.jaci.2020.08.013 https://doi.org/10.1016/j.jaci.2020.08.013 PMid:32841652

   31. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021; 320(3):C375-C391. https://doi.org/0.1152/ajpcell.00379.2020 https://doi.org/10.1152/ajpcell.00379.2020 PMid:33356944 PMCid:PMC8294624

   32. Sebo ZL, Rodeheffer MS. Assembling the adipose organ: Adipocyte lineage segragation and adipogenesis in vivo. Development. 2019; 146:dev172098. https://doi.org/10.1242/dev.172098 https://doi.org/10.1242/dev.172098 PMid:30948523 PMCid:PMC6467474

   33. Rutkowski JM, Stern JH, Scherer PE. The cell biology of fat expansion. J Cell Biol. 2015; 208(5):501‐512. https://doi.org/10.1083/jcb.201409063 https://doi.org/10.1083/jcb.201409063 PMid:25733711 PMCid:PMC4347644

   34. Lafontan M, Langin D. Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res. 2009; 48(5):275-97. https://doi.org/10.1016/j.plipres.2009.05.001 https://doi.org/10.1016/j.plipres.2009.05.001 PMid:19464318

   35. Lee YS, Li P, Huh JY, Hwang IJ, Lu M, Kim JI, et al. Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes. 2011; 60: 2474-2483. https://doi.org/10.2337/db11-0194 https://doi.org/10.2337/db11-0194 PMid:21911747 PMCid:PMC3178297

   36. Trayhurn P, Wood IS. Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92:347-355. https://doi.org/10.1079/bjn20041213 https://doi.org/10.1079/BJN20041213 PMid:15469638

   37. Mohammed Saeed W, Nasser Binjawhar D. Association of Serum Leptin and Adiponectin Concentrations with Type 2 Diabetes Biomarkers and Complications Among Saudi Women. Diabetes Metab Syndr Obes. 2023; 16:2129-2140. https://doi.org/10.2147/DMSO.S405476 https://doi.org/10.2147/DMSO.S405476 PMid:37465649 PMCid:PMC10351522

   38. Chang Liu, Xiaojiao Li, Role of leptin and adiponectin in immune response and inflammation, International Immunopharmacology. 2025; 161. https://doi.org/10.1016/j.intimp.2025.115082 https://doi.org/10.1016/j.intimp.2025.115082 PMid:40516255

   39. Hong X, Zhang X, You L, Li F, Lian H, Wang J, et al. Association between adiponectin and newly diagnosed type 2 diabetes in population with the clustering of obesity, dyslipidaemia and hypertension: a cross-sectional study. BMJ Open. 2023; 13(2):e060377. https://doi.org/10.1136/bmjopen-2021-060377 https://doi.org/10.1136/bmjopen-2021-060377 PMid:36828662 PMCid:PMC9972409

   40. Buechler C, Feder S, Haberl EM, Aslanidis C. Chemerin Isoforms and Activity in Obesity. Int J Mol Sci. 2019; 20(5):1128. https://doi.org/10.3390/ijms20051128 https://doi.org/10.3390/ijms20051128 PMid:30841637 PMCid:PMC6429392

   41. Jialal I. Chemerin levels in metabolic syndrome: a promising biomarker. Arch Physiol Biochem. 2023; 129(5):1009-1011. https://doi.org/10.1080/13813455.2021.1912103 https://doi.org/10.1080/13813455.2021.1912103 PMid:33843397

   42. Gutierrez-Rodelo C, Arellano-Plancarte A, Hernandez-Aranda J, Landa-Galvan HV, Parra-Mercado GK, Moreno-Licona NJ, et al. Angiotensin II Inhibits Insulin Receptor Signaling in Adipose Cells. International Journal of Molecular Sciences. 2022; 23(11):6048. https://doi.org/10.3390/ijms23116048 https://doi.org/10.3390/ijms23116048 PMid:35682723 PMCid:PMC9181642

   43. Munno M, Mallia A, Greco A, Modafferi G, Banfi C, Eligini S. Radical Oxygen Species, Oxidized Low-Density Lipoproteins, and Lectin-like Oxidized Low-Density Lipoprotein Receptor 1: A Vicious Circle in Atherosclerotic Process. Antioxidants (Basel). 2024; 13(5):583. https://doi.org/10.3390/antiox13050583 https://doi.org/10.3390/antiox13050583 PMid:38790688 PMCid:PMC11118168

   44. Craige SM, Kaur G, Bond JM, Caliz AD, Kant S, Keaney JF. Endothelial Reactive Oxygen Species: Key Players in Cardiovascular Health and Disease. ARS. Redox Signaling. 2025; 42(16-18):905-932. https://doi.org/10.1089/ars.2024.0706 https://doi.org/10.1089/ars.2024.0706 PMid:39213161

   45. Rabiee A, Hossain MA, Poojari A. Adipose Tissue Insulin Resistance: A Key Driver of Metabolic Syndrome Pathogenesis. Biomedicines. 2025; 13(10):2376. https://doi.org/10.3390/biomedicines13102376 https://doi.org/10.3390/biomedicines13102376 PMid:41153663 PMCid:PMC12561392

   46. Dhakad PK, Mishra R, Mishra I. Toll-like receptor expression during inflammatory processes in human diseases. Rheumatol Autoimmun. 2025; 5:1-14. https://doi.org/10.1002/rai2.12167 https://doi.org/10.1002/rai2.12167

   47. Campos-Bayardo TI, Román-Rojas D, García-Sánchez A, Cardona-Muñoz EG, Sánchez-Lozano DI, Totsuka-Sutto S, et al. The Role of TLRs in Obesity and Its Related Metabolic Disorders. International Journal of Molecular Sciences. 2025; 26(5):2229. https://doi.org/10.3390/ijms26052229 https://doi.org/10.3390/ijms26052229 PMid:40076851 PMCid:PMC11900219

   48. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Investig. 2006; 116:3015-3025. https://doi.org/10.1172/JCI28898 https://doi.org/10.1172/JCI28898 PMid:17053832 PMCid:PMC1616196

   49. Himes RW, Smith CW. Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J. 2010; 24(3):731-9. https://doi.org/10.1096/fj.09-141929 https://doi.org/10.1096/fj.09-141929 PMid:19841034 PMCid:PMC2830137

   50. Jialal I, Huet BA, Kaur H, Chien A, Devaraj S. Increased toll-like receptor activity in patients with metabolic syndrome. Diabetes Care. 2012; 35(4):900-4. https://doi.org/10.2337/dc11-2375 https://doi.org/10.2337/dc11-2375 PMid:22357188 PMCid:PMC3308307

   51. Lim PS, Chang YK, Wu TK. Serum Lipopolysaccharide-Binding Protein is Associated with Chronic Inflammation and Metabolic Syndrome in Hemodialysis Patients. Blood Purif. 2019; 47:28-36. https://doi.org/10.1159/000492778leber https://doi.org/10.1159/000492778 PMid:30219816

   52. Leber B, Tripolt NJ, Blattl D, Eder M, Wascher TC, Pieber TR, et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: An open label, randomized pilot study. Eur J Clin Nutr. 2012; 66:1110-1115. https://doi.org/10.1038/ejcn.2012.103 https://doi.org/10.1038/ejcn.2012.103 PMid:22872030

   53. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Investig. 2003; 112:1796-1808. https://doi.org/10.1172/JCI19246 https://doi.org/10.1172/JCI19246 PMid:14679176 PMCid:PMC296995

   54. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836-843. https://doi.org/10.1056/NEJM200003233421202 https://doi.org/10.1056/NEJM200003233421202 PMid:10733371

   55. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004; 94:534-541. https://doi.org/10.1161/01.RES.0000115557.25127.8D https://doi.org/10.1161/01.RES.0000115557.25127.8D PMid:14699015

   56. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci. 1994; 91:4854-4858. https://doi.org/10.1073/pnas.91.11.4854 https://doi.org/10.1073/pnas.91.11.4854 PMid:8197147 PMCid:PMC43887

   57. Tchernof A, Bélanger C, Morisset AS, Richard C, Mailloux J, Laberge P, et al. Regional Differences in Adipose Tissue Metabolism in Women: Minor Effect of Obesity and Body Fat Distribution. Diabetes. 2006; 55 (5):1353-1360. https://doi.org/10.2337/db05-1439 https://doi.org/10.2337/db05-1439 PMid:16644692

   58. Fang L, Guo F, Zhou L, Stahl R, Grams J. The cell size and distribution of adipocytes from subcutaneous and visceral fat is associated with type 2 diabetes mellitus in humans. Adipocyte. 2015; 4(4):273-9. https://doi.org/10.1080/21623945.2015.1034920 https://doi.org/10.1080/21623945.2015.1034920 PMid:26451283 PMCid:PMC4573191

   59. Hoffstedt J, Arner E, Wahrenberg H, et al. Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity. Diabetologia. 2010; 53:2496-2503. https://doi.org/10.1007/s00125-010-1889-3 https://doi.org/10.1007/s00125-010-1889-3 PMid:20830466

   60. Veilleux A, Caron-Jobin M, Noël S, Laberge PY, Tchernof A. Visceral adipocyte hypertrophy is associated with dyslipidemia independent of body composition and fat distribution in women. Diabetes. 2011; 60(5):1504-11. https://doi.org/10.2337/db10-1039 https://doi.org/10.2337/db10-1039 PMid:21421806 PMCid:PMC3292324

   61. McLaughlin T, Lamendola C, Coghlan N, Liu TC, Lerner K, Sherman A, et al. Subcutaneous adipose cell size and distribution: relationship to insulin resistance and body fat. Obesity (Silver Spring). 2014; 22(3):673-80. https://doi.org/10.1002/oby.20209 https://doi.org/10.1002/oby.20209 PMid:23666871 PMCid:PMC4344365

   62. Lönn M, Mehlig K, Bengtsson C, Lissner L. Adipocyte size predicts incidence of type 2 diabetes in women. FASEB J. 2010; 24: 326-331. https://doi.org/10.1096/fj.09-133058 https://doi.org/10.1096/fj.09-133058 PMid:19741173

   63. Pasarica M, Xie H, Hymel D, et al. Lower total adipocyte number but no evidence for small adipocyte depletion in patients with type 2 diabetes. Diabetes Care. 2009; 32:900-902. https://doi.org/10.2337/dc08-2240 https://doi.org/10.2337/dc08-2240 PMid:19228873 PMCid:PMC2671122

   64. Zand H, Morshedzadeh N, Naghashian F. Signaling pathways linking inflammation to insulin resistance. Diabetes Metab Syndr. 2017; 11(Suppl 1):S307-9. https://doi.org/10.1016/j.dsx.2017.03.006 PMid:28365222

   65. Sun, Y, Lin, X, Zou, Z, et al. Association between visceral fat area and metabolic syndrome in individuals with normal body weight: insights from a Chinese health screening dataset. Lipids Health Dis. 2025; 24(57). https://doi.org/10.1186/s12944-025-02482-0 https://doi.org/10.1186/s12944-025-02482-0 PMid:39966964 PMCid:PMC11837645

   66. Lee A, Kim YJ, Oh SW, Lee CM, Choi HC, Joh HK, et al. Cut-off values for visceral Fat Area identifying Korean adults at risk for metabolic syndrome. Korean J Fam Med. 2018; 39:239-46. https://doi.org/10.4082/kjfm.17.0099 PMid:29972898 PMCid:PMC6056408

   67. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, et al. Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese americans. Diabetes Care. 2003; 26:650-5. https://doi.org/10.2337/diacare.26.3.650 PMid:12610016

   68. Yang J, Eliasson B, Smith U, Cushman SW. Sherman AS. The Size of Large Adipose Cells Is a Predictor of Insulin Resistance in First-Degree Relatives of Type 2 Diabetic Patients. Obesity. 2012; 20:932-938. https://doi.org/10.1038/oby.2011.371 https://doi.org/10.1038/oby.2011.371 PMid:22240722 PMCid:PMC3457700

   69. Czerwiec K, Zawrzykraj M, Deptuła M, Skoniecka A, Tymińska A, Zieliński J, et al. Adipose-Derived Mesenchymal Stromal Cells in Basic Research and Clinical Applications. Int J Mol Sci. 2023; 24(4):3888. https://doi.org/10.3390/ijms24043888 https://doi.org/10.3390/ijms24043888 PMid:36835295 PMCid:PMC9962639

   70. Baglioni S, Cantini G, Poli G, Francalanci M, Squecco R, Di Franco A, et al. Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. PLoS One. 2012; 7(5):e36569. https://doi.org/10.1371/journal.pone.0036569 https://doi.org/10.1371/journal.pone.0036569 PMid:22574183 PMCid:PMC3344924

   71. Yazmín Macotela, Brice Emanuelli, Marcelo A. Mori, Stephane Gesta, Tim J. Schulz, Yu-Hua Tseng, et al. Intrinsic Differences in Adipocyte Precursor Cells From Different White Fat Depots. Diabetes. 2012; 61 (7):1691-1699. https://doi.org/10.2337/db11-1753 https://doi.org/10.2337/db11-1753 PMid:22596050 PMCid:PMC3379665

   72. Qiu G, Zheng G, Ge M, et al. Mesenchymal stem cell‐derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res Ther. 2018; 9(1):1‐9. https://doi.org/10.1186/s13287-018-1069-9 https://doi.org/10.1186/s13287-018-1069-9 PMid:30463593 PMCid:PMC6249826

   73. Eirin A, Zhu XY, Puranik AS, Woollard JR, Tang H, Dasari S, et al. Integrated transcriptomic and proteomic analysis of the molecular cargo of extracellular vesicles derived from porcine adipose tissue-derived mesenchymal stem cells. PLoS One. 2017; 12(3):e0174303. https://doi.org/10.1371/journal.pone.0174303 https://doi.org/10.1371/journal.pone.0174303 PMid:28333993 PMCid:PMC5363917

   74. Nancarrow-Lei R, Mafi P, Mafi R, Khan W. A systemic review of adult mesenchymal stem cell sources and their multilineage differentiation potential relevant to musculoskeletal tissue repair and regeneration. Curr. Stem Cell Res. Ther. 2017; 12:601-610. https://doi.org/10.2174/1574888X12666170608124303 https://doi.org/10.2174/1574888X12666170608124303 PMid:28595566

   75. Huang X, Huang L, Lu J, et al. The relationship between telomere length and aging-related diseases. Clin Exp Med. 2025; 25(72). https://doi.org/10.1007/s10238-025-01608-z https://doi.org/10.1007/s10238-025-01608-z PMid:40044947 PMCid:PMC11882723

   76. Oñate B, Vilahur G, Camino‐López S, et al. Stem cells isolated from adipose tissue of obese patients show changes in their transcriptomic profile that indicate loss in stemcellness and increased commitment to an adipocyte‐like phenotype. BMC Genomics. 2013; 14(1):625‐637. https://doi.org/10.1186/1471‐2164‐14‐625 https://doi.org/10.1186/1471-2164-14-625 PMid:24040759 PMCid:PMC3848661

   77. Silva KR, Liechocki S, Carneiro JR, et al. Stromal-vascular fraction content and adipose stem cell behavior are altered in morbid obese and post bariatric surgery ex-obese women. Stem Cell Res Ther. 2015; 6(1):72. https://doi.org/10.1186/s13287-015-0029-x https://doi.org/10.1186/s13287-015-0029-x PMid:25884374 PMCid:PMC4435525

   78. Oliva-Olivera W, Lhamyani S, Coin-Araguez L, et al. Neovascular deterioration, impaired NADPH oxidase and inflammatory cytokine expression in adipose-derived multipotent cells from subjects with metabolic syndrome. Metabolism. 2017; 71:132-143. https://doi.org/10.1016/j.metabol.2017.03.012 https://doi.org/10.1016/j.metabol.2017.03.012 PMid:28521866

   79. Barbagallo I, Li Volti G, Galvano F, Tettamanti G, Pluchinotta FR, Bergante S, et al. Diabetic human adipose tissue-derived mesenchymal stem cells fail to differentiate in functional adipocytes. Exp Biol Med (Maywood). 2017; 242(10):1079-1085. https://doi.org/10.1177/1535370216681552 https://doi.org/10.1177/1535370216681552 PMid:27909015 PMCid:PMC5444636

   80. López R, Martí-Chillón GJ, Blanco JF, da Casa C, González-Robledo J, Pescador D, et al. MSCs from polytrauma patients: preliminary comparative study with MSCs from elective-surgery patients. Stem Cell Res Ther. 2021; 12(1):451. https://doi.org/10.1186/s13287-021-02500-9 https://doi.org/10.1186/s13287-021-02500-9 PMid:34380565 PMCid:PMC8356428

   81. Martí-Chillón GJ, Muntión S, Preciado S, Osugui L, Navarro-Bailón A, González-Robledo J, et al. Therapeutic potential of mesenchymal stromal/stem cells in critical-care patients with systemic inflammatory response syndrome. Clin Transl Med. 2023; 13(1):e1163. https://doi.org/10.1002/ctm2.1163 https://doi.org/10.1002/ctm2.1163 PMid:36588089 PMCid:PMC9806020

   82. Gkrinia EMM, Belančić A. The Mechanisms of Chronic Inflammation in Obesity and Potential Therapeutic Strategies: A Narrative Review. Curr Issues Mol Biol. 2025; 47(357). https://doi.org/10.3390/cimb47050357 https://doi.org/10.3390/cimb47050357 PMid:40699756 PMCid:PMC12110701

   83. Song N, Scholtemeijer MSK. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020; 41(9):653‐664. https://doi.org/10.1016/j.tips.2020.06.009 https://doi.org/10.1016/j.tips.2020.06.009 PMid:32709406 PMCid:PMC7751844

   84. Müller L, Tunger A, Wobus M, et al. Immunomodulatory properties of mesenchymal stromal cells: an update. Front Cell Dev Biol. 2021; 9:1‐9. https://doi.org/10.3389/fcell.2021.637725 https://doi.org/10.3389/fcell.2021.637725 PMid:33634139 PMCid:PMC7900158

   85. Laroye C, Gibot S, Reppel L, Bensoussan D. Concise review: mesenchymal stromal/stem cells: a new treatment for sepsis and septic shock? Stem Cells. 2017; 35(12):2331‐2339. https://doi.org/10.1002/stem.2695 https://doi.org/10.1002/stem.2695 PMid:28856759

   86. Huang X, Liu Y, Li Z, Lerman LO. Mesenchymal Stem/Stromal Cells Therapy for Metabolic Syndrome: Potential Clinical Application? Stem Cells. 2023; 41(10):893-906. https://doi.org/10.1093/stmcls/sxad052 https://doi.org/10.1093/stmcls/sxad052 PMid:37407022 PMCid:PMC10560401

   87. Jiang D, Muschhammer J, Qi Y, Kügler A, de Vries JC, Saffarzadeh M, et al. Suppression of Neutrophil-Mediated Tissue Damage-A Novel Skill of Mesenchymal Stem Cells. Stem Cells. 2016; 34(9):2393-406. https://doi.org/10.1002/stem.2417 https://doi.org/10.1002/stem.2417 PMid:27299700 PMCid:PMC5572139

   88. Qi Y, Liu W, Wang X, et al. Adipose-derived mesenchymal stem cells from obese mice prevent body weight gain and hyperglycemia. Stem Cell Res Ther. 2021; 12(1):277. https://doi.org/10.1186/s13287-021-02357-y https://doi.org/10.1186/s13287-021-02357-y PMid:33957965 PMCid:PMC8101155

   89. Chen H, Chen X, Zhou Zh, et al. Mesenchymal stromal cell-mediated mitochondrial transfer unveils new frontiers in disease therapy. Stem Cell Res Ther. 2025; 16(546). https://doi.org/10.1186/s13287-025-04675-x https://doi.org/10.1186/s13287-025-04675-x PMid:41063290 PMCid:PMC12505854

   90. Chen G, Fan XY, Zheng XP, Jin YL, Liu Y, Liu SC. Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance via PTEN-mediated crosstalk between the PI3K/Akt and Erk/MAPKs signaling pathways in the skeletal muscles of db/db mice. Stem Cell Res Ther. 2020; 11(1):401. https://doi.org/10.1186/s13287-020-01865-7 https://doi.org/10.1186/s13287-020-01865-7 PMid:32938466 PMCid:PMC7493876

   91. Qi Y, Liu W, Wang X, et al. Adipose-derived mesenchymal stem cells from obese mice prevent body weight gain and hyperglycemia. Stem Cell Res Ther. 2021; 12(1):277. https://doi.org/10.1186/s13287-021-02357-y https://doi.org/10.1186/s13287-021-02357-y PMid:33957965 PMCid:PMC8101155

   92. Kotikalapudi N, Sampath SJP, Sinha SN, Bhonde R, Mungamuri SK, Venkatesan V. Human placental mesenchymal stromal cell therapy restores the cytokine efflux and insulin signaling in the skeletal muscle of obesity-induced type 2 diabetes rat model. Hum Cell. 2022; 35(2):557-571. https://doi.org/10.1007/s13577-021-00664-3 https://doi.org/10.1007/s13577-021-00664-3 PMid:35091972

   93. Kotikalapudi N, Sampath SJP, Sinha SN, Bhonde R, Mungamuri SK, Venkatesan V. Placental mesenchymal stem cells restore glucose and energy homeostasis in obesogenic adipocytes. Cell Tissue Res. 2023; 391(1):127-144. https://doi.org/10.1007/s00441-022-03693-y https://doi.org/10.1007/s00441-022-03693-y PMid:36227376

   94. Hu J, Fu Z, Chen Y, et al. Effects of autologous adipose-derived stem cell infusion on type 2 diabetic rats. Endocr J. 2015; 62(4):339-352. https://doi.org/10.1507/endocrj.EJ14-0584 https://doi.org/10.1507/endocrj.EJ14-0584 PMid:25739585

   95. Huang X, Liu Y, Li Z, Lerman LO. Mesenchymal Stem/Stromal Cells Therapy for Metabolic Syndrome: Potential Clinical Application? Stem Cells. 2023; 41(10):893-906. https://doi.org/10.1093/stmcls/sxad052 https://doi.org/10.1093/stmcls/sxad052 PMid:37407022 PMCid:PMC10560401

   96. Xie Z, Cheng Y, Zhang Q, et al. Anti-obesity effect and mechanism of mesenchymal stem cells influence on obese mice. Open Life Sci. 2021; 16(1):653-666. https://doi.org/10.1515/biol-2021-0061 https://doi.org/10.1515/biol-2021-0061 PMid:34222665 PMCid:PMC8234810

   97. Jaber H, Issa K, Eid A, Saleh FA. The therapeutic effects of adiposederived mesenchymal stem cells on obesity and its associated diseases in diet-induced obese mice. Sci Rep. 2021; 11(1):6291. https://doi.org/10.1038/s41598-021-85917-9 https://doi.org/10.1038/s41598-021-85917-9 PMid:33737713 PMCid:PMC7973738

   98. Domingues CC, Kundu N, Kropotova Y, Ahmadi N, Sen S. Antioxidant‐upregulated mesenchymal stem cells reduce inflammation and improve fatty liver disease in diet‐induced obesity. Stem Cell Res Ther. 2019; 10(1):1‐10. https://doi.org/10.1186/s13287‐019‐1393‐8 https://doi.org/10.1186/s13287-019-1393-8 PMid:31477174 PMCid:PMC6720095

   99. Chow L, Johnson V, Impastato R, Coy J, Strumpf A, Dow S. Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells. Stem Cells Transl Med. 2020; 9(2):235-249. https://doi.org/10.1002/sctm.19-0092 https://doi.org/10.1002/sctm.19-0092 PMid:31702119 PMCid:PMC6988770

   100. Moeinabadi-Bidgoli K, Rezaee M, Rismanchi H, Mohammadi MM, Babajani A. Mesenchymal stem cell-derived antimicrobial peptides as potential anti-neoplastic agents: new insight into anticancer mechanisms of stem cells and exosomes. Review. Front Cell Dev Biology. 2022; 10. https://doi.org/10.3389/fcell.2022.900418 https://doi.org/10.3389/fcell.2022.900418 PMid:35874827 PMCid:PMC9298847

   101. Timper K, Seboek D, Eberhardt M, et al. Human adipose tissue‐derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochem Biophys Res Commun. 2006; 341(4):1135‐1140. https://doi.org/10.1016/j.bbrc.2006.01.07 https://doi.org/10.1016/j.bbrc.2006.01.072 PMid:16460677

   102. Lee J, Kim SC, Kim SJ, et al. Differentiation of human adipose tissue‐derived stem cells into aggregates of insulin‐producing cells through the overexpression of pancreatic and duodenal homeobox gene‐1. Cell Transplant. 2013; 22(6):1053‐1060. https://doi.org/10.3727/096368912X657215 https://doi.org/10.3727/096368912X657215 PMid:23031216

   103. Dave S, Vanikar A, Trivedi H. Ex vivo generation of glucose sensitive insulin secreting mesenchymal stem cells derived from human adipose tissue. Indian J Endocrinol Metab. 2012; 16(7):S65‐S69. https://doi.org/10.4103/2230‐8210.94264 https://doi.org/10.4103/2230-8210.94264 PMid:22701849 PMCid:PMC3354929

   104. Karaoz E, Okcu A, Ünal ZS, Subasi C, Saglam O, Duruksu G. Adipose tissue‐derived mesenchymal stromal cells efficiently differentiate into insulin‐producing cells in pancreatic islet microenvironment both in vitro and in vivo. Cytotherapy. 2013; 15(5):557‐570. https://doi.org/10.1016/j.jcyt.2013.01.005 https://doi.org/10.1016/j.jcyt.2013.01.005 PMid:23388582

   105. Huang X, Liu Y, Li Z, Lerman LO. Mesenchymal Stem/Stromal Cells Therapy for Metabolic Syndrome: Potential Clinical Application? Stem Cells. 2023; 41(10):893-906. https://doi.org/10.1093/stmcls/sxad052 https://doi.org/10.1093/stmcls/sxad052 PMid:37407022 PMCid:PMC10560401

   106. Varghese J, Griffin M, Mosahebi A, Butler P. Systematic review of patient factors affecting adipose stem cell viability and function: implications for regenerative therapy. Stem Cell Res Ther. 2017; 8:45. https://doi.org/10.1186/s13287-017- 0483-8 https://doi.org/10.1186/s13287-017-0483-8 PMid:28241882 PMCid:PMC5329955

   107. Alicka M, Major P, Wysocki M, Marycz K. Adipose-derived mesenchymal stem cells isolated from patients with type 2 diabetes show reduced “stemness” through an altered secretome profile, impaired anti-oxidative protection, and mitochondrial dynamics deterioration. J Clin Med. 2019; 8(6):765. https://doi.org/10.3390/jcm8060765 https://doi.org/10.3390/jcm8060765 PMid:31151180 PMCid:PMC6617220

   108. Abu-Shahba N, Mahmoud M, El-Erian AM, et al. Impact of type 2 diabetes mellitus on the immunoregulatory characteristics of adipose tissue-derived mesenchymal stem cells. Int J Biochem Cell Biol. 2021; 140:106072. https://doi.org/10.1016/j.biocel.2021.106072 https://doi.org/10.1016/j.biocel.2021.106072 PMid:34455058

Ivanishchev V, Ustymenko A. Adipose tissue dysfunction under inflammatory conditions and possibilities for its correction using cell therapy. Cell Organ Transpl. 2025; 13(2):e2025132184. doi: 10.22494/cot.v13-2.184